A PHASE 2 RANDOMISED OPEN TWO-ARM STUDY TO ASSESS THE TOLERABILITY AND EFFICACY OF IMMUNOTHERAPY COMBINED WITH EXTENSIVE RADIATIOTHERAPY FOR THE TREATMENT OF STAGE IV NON-SMALL CELL LUNG CANCER
Latest Information Update: 24 Jun 2024
At a glance
- Drugs Atezolizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms Com-IT-2
Most Recent Events
- 09 Mar 2022 New trial record